David Lloyd

David Lloyd

Available For Media Comment.

Professor David Lloyd is Vice Chancellor and President of the University of South Australia and co-Vice Chancellor of Adelaide University. 
A Dublin-born and educated chemist with a specialisation in computer-aided drug design, Prof Lloyd has positioned UniSA as Australia's university of enterprise, reshaping the institution’s activities to better meet the challenges of today’s learners. Most recently he has co-led the creation of the new Adelaide University – the first comprehensive public Australian university to be created this century – formed through the amalgamation of the University of Adelaide and the University of South Australia.
Prof Lloyd is currently a ministerially-appointed member of the Australian Universities Accord Implementation Advisory Committee (IAC). He has chaired the Australian Technology Network – a group of technology-focused universities – and Universities Australia (UA), the peak body representing the university sector. He was also UA's lead Vice Chancellor for Indigenous issues and for Research and Innovation. Additionally, Prof Lloyd served on the Australian Research Council’s (ARC) Advisory Committee, where he helped enhance the ARC’s ability to support research and innovation in Australia by providing advice on strategy and key research policy issues. Prof Lloyd was also a member of South Australia’s Economic Development Board (EDB) from 2014 to 2018. 
Before joining UniSA, Prof Lloyd was Vice President for Research, and later, Bursar and Director of Strategic Innovation at Trinity College Dublin. Prof Lloyd was also Chair of the Irish Research Council and, prior to entering academia, worked in the pharmaceutical industry in the UK. He holds an Honorary Professorship from Tianjin University and is a Fellow of the Royal Society of Chemistry and the Australian Academy of Technology and Engineering. 
Prof Lloyd holds a Bachelor of Science (Honours) in Applied Chemistry and a PhD in Medicinal Organic Chemistry from Dublin City University. He also holds an MA (j.o.) from Trinity College and an Honorary Doctorate from the late Sir Terry Pratchett’s Unseen University. 

Year Citation
2020 Carr, M., Knox, A. J. S., Nevin, D. K., O'Boyle, N., Wang, S., Egan, B., . . . Meegan, M. J. (2020). Optimisation of estrogen receptor subtype-selectivity of a 4-Aryl-4H-chromene scaffold previously identified by virtual screening. Bioorganic and Medicinal Chemistry, 28(5, article no. 115261), 1-16.
DOI
2016 Carr, M., Knox, A. J. S., Lloyd, D. G., Zisterer, D. M., & Meegan, M. J. (2016). Development of the β-lactam type molecular scaffold for selective estrogen receptor α modulator action: synthesis and cytotoxic effects in MCF-7 breast cancer cells. Journal of enzyme inhibition and medicinal chemistry, 31(sup3), 117-130.
DOI
2016 Keely, N. O., Carr, M., Yassin, B., Ana, G., Lloyd, D. G., Zisterer, D., & Meegan, M. J. (2016). Design, synthesis and biochemical evaluation of novel selective estrogen receptor ligand conjugates incorporating an endoxifen-combretastatin hybrid scaffold. Biomedicines, 4(15), 1-34.
DOI Europe PMC11
2014 Mawhinney, L., Armstrong, M. E., O'Reilly, C., Bucala, R., Leng, L., Fingerle Rowson, G., . . . Donnelly, S. C. (2014). Macrophage migration inhibitory factor (MIF) enzymatic activity and lung cancer. Molecular medicine, 20(1), 729-735.
DOI
2014 Diez Cecilia, E., Kelly, B., Perez, C., Zisterer, D. M., Nevin, D. K., Lloyd, D. G., & Rozas, I. (2014). Guanidinium-based derivatives : searching for new kinase inhibitors. European journal of medicinal chemistry, 81, 427-441.
DOI
2014 Kesel, A. J., Huang, Z., Murray, M. G., Prichard, M. N., Caboni, L., Nevin, D. K., . . . Schinazi, R. F. (2014). Retinazone inhibits certain blood-borne human viruses including Ebola virus Zaire. Antiviral chemistry & chemotherapy, 23(5), 197-215.
DOI Scopus15 Europe PMC12
2014 Caboni, L., Gálvez Llompart, M., Gálvez, J., Blanco, F., Rubio Martinez, J., Fayne, D., & Lloyd, D. G. (2014). Molecular topology applied to the discovery of 1-benzyl-2-(3-fluorophenyl)-4-hydroxy-3-(3-phenylpropanoyl)-2H-pyrrole-5-one as a non-ligand-binding-pocket antiandrogen. Journal of chemical information and modeling, 54(10), 2953-2966.
DOI
2014 Blanco, F., Lloyd, D. G., Alkorta, I., & Elguero, J. (2014). Neutral alkaline-metal and alkaline-earth-metal derivatives of imidazole and benzimidazole. The journal of physical chemistry A, 118(23), 4195-4204.
DOI
2013 Lloyd, D. G. (2013). Approaches to scaffold hopping. Drug Discovery Today: Technologies, 10(4), 451.
DOI
2013 Caboni, L., & Lloyd, D. G. (2013). Beyond the ligand-binding pocket: targeting alternate sites in nuclear receptors. Medicinal research reviews, 33(5), 1081-1118.
DOI
2013 Caboni, L., Egan, B., Kelly, B., Blanco, F., Fayne, D., Meegan, M. J., & Lloyd, D. G. (2013). Structure-activity relationships in non-ligand binding pocket (non-LBP) diarylhydrazide antiandrogens. Journal of chemical information and modeling, 58(8), 2116-2130.
DOI
2013 Blanco, F., Lloyd, D. G., Azofra, L. M., Alkorta, I., & Elguero, J. (2013). Theoretical studies of parent 1- ,2- , 3-pyrazolines and their methylated derivatives. Structural chemistry, 24(2), 421-432.
DOI
2012 Mckay, P. B., Fayne, D., Horn, H. W., James, T., Peters, M. B., Carta, G., . . . Lloyd, D. G. (2012). Consensus computational ligand-based design for the identification of novel modulators of human estrogen receptor alpha. Molecular informatics, 31(3-4), 246-258.
DOI
2012 Caboni, L., Kinsella, G. K., Blanco, F., Fayne, D., Jagoe, W. N., Carr, M., . . . Lloyd, D. G. (2012). "True" antiandrogens - selective non-ligand-binding pocket disruptors of androgen receptor-coactivator interactions : novel tools for prostate cancer. Journal of medicinal chemistry, 55(4), 1635-1644.
DOI
2012 Nevin, D. K., Peters, M. B., Carta, G., Fayne, D., & Lloyd, D. G. (2012). Integrated virtual screening for the identification of novel and selective peroxisome proliferator-activated receptor (PPAR) scaffolds. Journal of medicinal chemistry, 55(11), 4978-4989.
DOI
2012 Blanco, F., Egan, B., Caboni, L., Elguero, J., O'Brien, J., McCabe, T., . . . Lloyd, D. G. (2012). Study of E/Z isomerization in a series of novel non-ligand binding pocket androgen receptor antagonists. Journal of chemical information and modeling, 52(9), 2387-2397.
DOI
2011 Nevin, D. K., Lloyd, D. G., & Fayne, D. (2011). Rational targeting of peroxisome proliferating activated receptor subtypes. Current medicinal chemistry, 18(36), 5598-5623.
2011 O'Boyle, N. M., Greene, L. M., Bergin, O., Fichet, J. B., McCabe, T., Lloyd, D. G., . . . Meegan, M. J. (2011). Synthesis, evaluation and structural studies of antiproliferative tubulin-targeting azetidin-2-ones. Bioorganic and medicinal chemistry, 19(7), 2306-2325.
DOI
2011 O'Boyle, N. M., Knox, A. J. S., Price, T. T., Williams, D. C., Zisterer, D. M., Lloyd, D. G., & Meegan, M. J. (2011). Lead identification of β-lactam and related imine inhibitors of the molecular chaperone heat shock protein 90. Bioorganic and medicinal chemistry, 19(20), 6055-6068.
DOI
2011 Mckay, P. B., Peters, M. B., Carta, G., Flood, C. T., Dempsey, E., Bell, A., . . . Fayne, D. (2011). Identification of plasmepsin inhibitors as selective anti-malarial agents using ligand based drug design. Bioorganic and medicinal chemistry letters, 21(11), 3335-3341.
DOI
2011 O'Boyle, N. M., Carr, M., Greene, L. M., Keely, N. O., Knox, A. J. S., McCabe, T., . . . Meegan, M. J. (2011). Synthesis, biochemical and molecular modelling studies of antiproliferative azetidinones causing microtubule disruption and mitotic catastrophe. European journal of medicinal chemistry, 46(9), 4595-4607.
DOI
2010 Nathwani, S. M., Butler, S., Fayne, D., McGovern, N. N., Sarkadi, B., Meegan, M. J., . . . Zisterer, D. M. (2010). Novel microtubule-targeting agents, pyrrolo-1,5-benzoxazepines, induce apoptosis in multi-drug-resistant cancer cells. Cancer chemotherapy and pharmacology, 66(3), 585-596.
DOI
2010 Carr, M., Greene, L. M., Knox, A. J. S., Lloyd, D. G., Zisterer, D. M., & Meegan, M. J. (2010). Lead identification of conformationally restricted β-lactam type combretastatin analogues : synthesis, antiproliferative activity and tubulin targeting effects. European journal of medicinal chemistry, 45(12), 5752-5766.
DOI
2010 Barrett, I., Carr, M., O'Boyle, N. M., Greene, L. M., Knox, A. J. S., Lloyd, D. G., . . . Meegan, M. J. (2010). Lead identification of conformationally restricted benzoxepin type combretastatin analogs : synthesis, antiproliferative activity, and tubulin effects. Journal of enzyme inhibition and medicinal chemistry, 25(2), 180-194.
DOI
2010 Greene, L. M., Nathwani, S. M., Bright, S. A., Fayne, D., Croke, A., Gagliardi, M., . . . Zisterer, D. M. (2010). The vascular targeting agent combretastatin-A4 and a novel cis-restricted ß-lactam analogue, CA-432, induce apoptosis in human chronic myeloid leukemia cells and ex vivo patient samples including those displaying multidrug resistance. Journal of pharmacology and experimental therapeutics, 335(2), 302-313.
DOI
2010 O'Boyle, N. M., Carr, M., Greene, L. M., Bergin, O., Nathwani, S. M., McCabe, T., . . . Meegan, M. J. (2010). Synthesis and evaluation of azetidinone analogues of combretastatin A-4 as tubulin targeting agents. Journal of medicinal chemistry, 53(24), 8569-8584.
DOI
2010 Onnis, V., Kinsella, G. K., Carta, G., Jagoe, W. N., Price, T., Williams, D. C., . . . Lloyd, D. G. (2010). Virtual screening for the identification of novel nonsteroidal glucocorticoid modulators. Journal of medicinal chemistry, 53(8), 3065-3074.
DOI
2010 Yang, Y., Carta, G., Peters, M. B., Price, T., O'Boyle, N., Knox, A. J. S., . . . Lloyd, D. G. (2010). 'tieredScreen' - Layered virtual screening tool for the identification of novel estrogen receptor alpha modulators. Molecular informatics, 29(5), 421-430.
DOI
2009 Onnis, V., Kinsella, G. K., Carta, G., Fayne, D., & Lloyd, D. G. (2009). Rational ligand-based virtual screening and structure-activity relationship studies in the ligand-binding domain of the glucocorticoid receptor-α. Future medicinal chemistry, 1(3), 483-499.
DOI
2009 Knox, A. J. S., Price, T., Pawlak, M., Golfis, G., Flood, C. T., Fayne, D., . . . Lloyd, D. G. (2009). Integration of ligand and structure-based virtual screening for the identification of the first dual targeting agent for heat shock protein 90 (Hsp90) and tubulin. Journal of medicinal chemistry, 52(8), 2177-2180.
DOI
2009 Cloonan, S. M., Keating, J., Butler, S. G., Knox, A. J. S., Jorgensen, A. M., Peters, G. H., . . . Meegan, M. J. (2009). Synthesis and serotonin transporter activity of sulphur-substituted a-alkyl phenethylamines as a new class of anticancer agents. European journal of medicinal chemistry, 44(12), 4862-4888.
DOI
2009 Onnis, V., Kinsella, G. K., Carta, G., Fayne, D., & Lloyd, D. G. (2009). Rational structure-based drug design and optimization in the ligand-binding domain of the glucocorticoid receptor-α. Future medicinal chemistry, 1(2), 345-359.
DOI
2009 Veith, H., Southall, N., Huang, R., James, T., Fayne, D., Artemenko, N., . . . Auld, D. S. (2009). Comprehensive characterization of cytochrome P450 isozyme selectivity across chemical libraries. Nature biotechnology, 27(11), 1050-1055.
DOI
2008 Meegan, M. J., Carr, M., Knox, A. J. S., Zisterer, D. M., & Lloyd, D. G. (2008). β-Lactam type molecular scaffolds for antiproliferative activity: synthesis and cytotoxic effects in breast cancer cells. Journal of enzyme inhibition and medicinal chemistry, 23(5), 668-685.
DOI
2008 Barrett, I., Meegan, M. J., Hughes, R. B., Carr, M., Knox, A. J. S., Artemenko, N., . . . Lloyd, D. G. (2008). Synthesis, biological evaluation, structural-activity relationship, and docking study for a series of benzoxepin-derived estrogen receptor modulators. Bioorganic and medicinal chemistry, 16(21), 9554-9573.
DOI
2007 Larbig, G., Pickhardt, M., Lloyd, D. G., Schmidt, B., & Mandelkow, E. (2007). Screening for inhibitors of tau protein aggregation into Alzheimer paired helical filaments: a ligand based approach results in successful scaffold hopping. Current Alzheimer research, 4(3), 315-323.
DOI
2007 Meegan, M. J., Barrett, I., Zimmermann, J., Knox, A. J. S., Zisterer, D. M., & Lloyd, D. (2007). Benzothiepin-derived molecular scaffolds for estrogen receptor modulators: synthesis and antagonistic effects in breast cancer cells. Journal of Enzyme Inhibition and Medicinal Chemistry, 22(5), 655-666.
DOI
2006 Carta, G., Onnis, V., Knox, A. J. S., & Lloyd, D. G. (2006). Permuting input for more effective sampling of 3D conformer space. Journal of Computer Aided Molecular Design, 20(3), 179-190.
DOI
2006 Lloyd, D. G., Golfis, G., Knox, A. J. S., Fayne, D., Meegan, M. J., & Oprea, T. I. (2006). Oncology exploration: charting cancer medicinal chemistry space. Drug Discovery Today, 11(3-4), 149-159.
DOI
2006 Knox, A. J. S., Meegan, M. J., & Lloyd, D. G. (2006). Estrogen receptors: molecular interactions, virtual screening and future prospects. Current Topics In Medicinal Chemistry, 6(3), 217-243.
DOI

Year Citation
2010 Mandelkow, E., Mandelkow, E. M., Pickhardt, M., Biernat, J., Lloyd, D. G., Schmidt, B., & Larbig, G. (2010). US20100151064, Thiazolhydrazides for treatment of neurodegenerative diseases.
  • Email: a1237038@unisa.edu.au
  • Alternative Contact: Executive Assistantto the Vice Chancellor: Neha Choudhry -neha.choudhry@unisa.edu.au | phone: +618 8302 0921

Connect With Me

External Profiles

Other Links